Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells

Jian Min Wang, Hong Zheng, Yuichi Sugahara, Jun Tan, Shou Nan Yao, Eric Olson, Kotoku Kurachi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Development of a highly refined human factor IX (hFIX) expression vector system is critical for establishing a durable hemophilia B gene therapy. Here we report construction of a series of retroviral vectors and identification of an optimal basic structure and components for expressing hFIX in skeletal muscle cells. These vectors, which are derived from Moloney murine leukemia virus (MoMLV) with its enhancer sequence in the 3' long terminal repeat (LTR) deleted, contained internal hFIX expression units inserted in forward configuration without or with a viral vector intron sequence (pdL or pdLIn vector frame, respectively) or in inverted configuration without a viral vector intron sequence (pdLi frame). Internal expression units contained a hFIX cDNA or hFIX minigene (hIXm1 or hIXm2) derived from the hFIX cDNA by insertion of a shortened first intron sequence of the hFIX gene. Regardless of the promoter and vector frame used, both hIXm1 and hIXm2 gave 10- to 14-fold higher hFIX expression compared to those with hFIX cDNA. Internal hFIX transcriptional control units of these vectors were composed of various promoters linked with or without the muscle creatine kinase enhancer (Me) sequence. Promoters tested included those of α-actin (αA775), β-actin (βA280), cytochrome oxidase (CO1250 and CO650), myogenin (Mg1031 and Mg353), and Rous sarcoma virus (RSV). βA200, which was derived from βA280 by eliminating potential polyadenylation sites, was also tested. As extensively examined with the myogenin promoter, presence of one or multiple copies of Me in the vectors elevated the expression activity in myotubes by 4.5- to 19-fold over those without Me, but not significantly in myoblasts. Similar enhancements in expression activity with Me were also observed with other promoters, except those of RSV and CO. The latter two showed only modest enhancements in the presence of Me. As assayed with myotubes in culture, the general order of hFIX expression activity of various promoters with four copies of Me in the three different vector frames was βA280 ≃ βA200 > Mg353 > Mg1031 ≃ RSV ≃ CO650 ≃ (αA775 > CO1250. One exception was that CO650 showed significantly less activity in pdLi-type vectors than in the pdLIn vectors. Based on the systematic analyses of various structural components, a group of pdLi vectors consisting of βA200, two to four copies of Me, and hIXm2 was identified to have the optimal basic vector structure to be used in retrovirus for hFIX expression in differentiated skeletal muscle cells. The present studies provide the critical first step for establishing a highly refined hemophilia B gene therapy based on skeletal muscle-targeted hFIX gene transfer.

Original languageEnglish (US)
Pages (from-to)1743-1756
Number of pages14
JournalHuman Gene Therapy
Volume7
Issue number14
StatePublished - Sep 10 1996

Fingerprint

Factor IX
Muscle Cells
Rous sarcoma virus
Introns
Myogenin
Hemophilia B
Skeletal Muscle
Complementary DNA
Skeletal Muscle Fibers
Genetic Therapy
Actins
MM Form Creatine Kinase
Moloney murine leukemia virus
Polyadenylation
Terminal Repeat Sequences
Myoblasts
Electron Transport Complex IV
Retroviridae
Carbon Monoxide
Genes

ASJC Scopus subject areas

  • Genetics

Cite this

Wang, J. M., Zheng, H., Sugahara, Y., Tan, J., Yao, S. N., Olson, E., & Kurachi, K. (1996). Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells. Human Gene Therapy, 7(14), 1743-1756.

Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells. / Wang, Jian Min; Zheng, Hong; Sugahara, Yuichi; Tan, Jun; Yao, Shou Nan; Olson, Eric; Kurachi, Kotoku.

In: Human Gene Therapy, Vol. 7, No. 14, 10.09.1996, p. 1743-1756.

Research output: Contribution to journalArticle

Wang, JM, Zheng, H, Sugahara, Y, Tan, J, Yao, SN, Olson, E & Kurachi, K 1996, 'Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells', Human Gene Therapy, vol. 7, no. 14, pp. 1743-1756.
Wang, Jian Min ; Zheng, Hong ; Sugahara, Yuichi ; Tan, Jun ; Yao, Shou Nan ; Olson, Eric ; Kurachi, Kotoku. / Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells. In: Human Gene Therapy. 1996 ; Vol. 7, No. 14. pp. 1743-1756.
@article{916ad2ac6d684f3998f6ef4facf9c3af,
title = "Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells",
abstract = "Development of a highly refined human factor IX (hFIX) expression vector system is critical for establishing a durable hemophilia B gene therapy. Here we report construction of a series of retroviral vectors and identification of an optimal basic structure and components for expressing hFIX in skeletal muscle cells. These vectors, which are derived from Moloney murine leukemia virus (MoMLV) with its enhancer sequence in the 3' long terminal repeat (LTR) deleted, contained internal hFIX expression units inserted in forward configuration without or with a viral vector intron sequence (pdL or pdLIn vector frame, respectively) or in inverted configuration without a viral vector intron sequence (pdLi frame). Internal expression units contained a hFIX cDNA or hFIX minigene (hIXm1 or hIXm2) derived from the hFIX cDNA by insertion of a shortened first intron sequence of the hFIX gene. Regardless of the promoter and vector frame used, both hIXm1 and hIXm2 gave 10- to 14-fold higher hFIX expression compared to those with hFIX cDNA. Internal hFIX transcriptional control units of these vectors were composed of various promoters linked with or without the muscle creatine kinase enhancer (Me) sequence. Promoters tested included those of α-actin (αA775), β-actin (βA280), cytochrome oxidase (CO1250 and CO650), myogenin (Mg1031 and Mg353), and Rous sarcoma virus (RSV). βA200, which was derived from βA280 by eliminating potential polyadenylation sites, was also tested. As extensively examined with the myogenin promoter, presence of one or multiple copies of Me in the vectors elevated the expression activity in myotubes by 4.5- to 19-fold over those without Me, but not significantly in myoblasts. Similar enhancements in expression activity with Me were also observed with other promoters, except those of RSV and CO. The latter two showed only modest enhancements in the presence of Me. As assayed with myotubes in culture, the general order of hFIX expression activity of various promoters with four copies of Me in the three different vector frames was βA280 ≃ βA200 > Mg353 > Mg1031 ≃ RSV ≃ CO650 ≃ (αA775 > CO1250. One exception was that CO650 showed significantly less activity in pdLi-type vectors than in the pdLIn vectors. Based on the systematic analyses of various structural components, a group of pdLi vectors consisting of βA200, two to four copies of Me, and hIXm2 was identified to have the optimal basic vector structure to be used in retrovirus for hFIX expression in differentiated skeletal muscle cells. The present studies provide the critical first step for establishing a highly refined hemophilia B gene therapy based on skeletal muscle-targeted hFIX gene transfer.",
author = "Wang, {Jian Min} and Hong Zheng and Yuichi Sugahara and Jun Tan and Yao, {Shou Nan} and Eric Olson and Kotoku Kurachi",
year = "1996",
month = "9",
day = "10",
language = "English (US)",
volume = "7",
pages = "1743--1756",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "14",

}

TY - JOUR

T1 - Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells

AU - Wang, Jian Min

AU - Zheng, Hong

AU - Sugahara, Yuichi

AU - Tan, Jun

AU - Yao, Shou Nan

AU - Olson, Eric

AU - Kurachi, Kotoku

PY - 1996/9/10

Y1 - 1996/9/10

N2 - Development of a highly refined human factor IX (hFIX) expression vector system is critical for establishing a durable hemophilia B gene therapy. Here we report construction of a series of retroviral vectors and identification of an optimal basic structure and components for expressing hFIX in skeletal muscle cells. These vectors, which are derived from Moloney murine leukemia virus (MoMLV) with its enhancer sequence in the 3' long terminal repeat (LTR) deleted, contained internal hFIX expression units inserted in forward configuration without or with a viral vector intron sequence (pdL or pdLIn vector frame, respectively) or in inverted configuration without a viral vector intron sequence (pdLi frame). Internal expression units contained a hFIX cDNA or hFIX minigene (hIXm1 or hIXm2) derived from the hFIX cDNA by insertion of a shortened first intron sequence of the hFIX gene. Regardless of the promoter and vector frame used, both hIXm1 and hIXm2 gave 10- to 14-fold higher hFIX expression compared to those with hFIX cDNA. Internal hFIX transcriptional control units of these vectors were composed of various promoters linked with or without the muscle creatine kinase enhancer (Me) sequence. Promoters tested included those of α-actin (αA775), β-actin (βA280), cytochrome oxidase (CO1250 and CO650), myogenin (Mg1031 and Mg353), and Rous sarcoma virus (RSV). βA200, which was derived from βA280 by eliminating potential polyadenylation sites, was also tested. As extensively examined with the myogenin promoter, presence of one or multiple copies of Me in the vectors elevated the expression activity in myotubes by 4.5- to 19-fold over those without Me, but not significantly in myoblasts. Similar enhancements in expression activity with Me were also observed with other promoters, except those of RSV and CO. The latter two showed only modest enhancements in the presence of Me. As assayed with myotubes in culture, the general order of hFIX expression activity of various promoters with four copies of Me in the three different vector frames was βA280 ≃ βA200 > Mg353 > Mg1031 ≃ RSV ≃ CO650 ≃ (αA775 > CO1250. One exception was that CO650 showed significantly less activity in pdLi-type vectors than in the pdLIn vectors. Based on the systematic analyses of various structural components, a group of pdLi vectors consisting of βA200, two to four copies of Me, and hIXm2 was identified to have the optimal basic vector structure to be used in retrovirus for hFIX expression in differentiated skeletal muscle cells. The present studies provide the critical first step for establishing a highly refined hemophilia B gene therapy based on skeletal muscle-targeted hFIX gene transfer.

AB - Development of a highly refined human factor IX (hFIX) expression vector system is critical for establishing a durable hemophilia B gene therapy. Here we report construction of a series of retroviral vectors and identification of an optimal basic structure and components for expressing hFIX in skeletal muscle cells. These vectors, which are derived from Moloney murine leukemia virus (MoMLV) with its enhancer sequence in the 3' long terminal repeat (LTR) deleted, contained internal hFIX expression units inserted in forward configuration without or with a viral vector intron sequence (pdL or pdLIn vector frame, respectively) or in inverted configuration without a viral vector intron sequence (pdLi frame). Internal expression units contained a hFIX cDNA or hFIX minigene (hIXm1 or hIXm2) derived from the hFIX cDNA by insertion of a shortened first intron sequence of the hFIX gene. Regardless of the promoter and vector frame used, both hIXm1 and hIXm2 gave 10- to 14-fold higher hFIX expression compared to those with hFIX cDNA. Internal hFIX transcriptional control units of these vectors were composed of various promoters linked with or without the muscle creatine kinase enhancer (Me) sequence. Promoters tested included those of α-actin (αA775), β-actin (βA280), cytochrome oxidase (CO1250 and CO650), myogenin (Mg1031 and Mg353), and Rous sarcoma virus (RSV). βA200, which was derived from βA280 by eliminating potential polyadenylation sites, was also tested. As extensively examined with the myogenin promoter, presence of one or multiple copies of Me in the vectors elevated the expression activity in myotubes by 4.5- to 19-fold over those without Me, but not significantly in myoblasts. Similar enhancements in expression activity with Me were also observed with other promoters, except those of RSV and CO. The latter two showed only modest enhancements in the presence of Me. As assayed with myotubes in culture, the general order of hFIX expression activity of various promoters with four copies of Me in the three different vector frames was βA280 ≃ βA200 > Mg353 > Mg1031 ≃ RSV ≃ CO650 ≃ (αA775 > CO1250. One exception was that CO650 showed significantly less activity in pdLi-type vectors than in the pdLIn vectors. Based on the systematic analyses of various structural components, a group of pdLi vectors consisting of βA200, two to four copies of Me, and hIXm2 was identified to have the optimal basic vector structure to be used in retrovirus for hFIX expression in differentiated skeletal muscle cells. The present studies provide the critical first step for establishing a highly refined hemophilia B gene therapy based on skeletal muscle-targeted hFIX gene transfer.

UR - http://www.scopus.com/inward/record.url?scp=0029818271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029818271&partnerID=8YFLogxK

M3 - Article

C2 - 8886845

AN - SCOPUS:0029818271

VL - 7

SP - 1743

EP - 1756

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 14

ER -